Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRN-1201 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BrightPath Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
GRN-1201 + pembrolizumab is a combination therapy under investigation for the treatment of certain cancers, notably melanoma and non-small cell lung cancer (NSCLC). GRN-1201 is a cancer vaccine composed of four HLA-A2-restricted peptides derived from tumor-associated antigens (TAAs), designed to stimulate the immune system to recognize and attack tumor cells by activating cytotoxic T lymphocytes. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 receptor (PD-1) on T cells, blocking its interaction with PD-L1 and thereby enhancing anti-tumor immune responses. The combination aims to synergistically boost anti-tumor immunity by both priming T-cell responses against specific tumor antigens (via GRN-1201) and preventing immune evasion by tumors (via PD-1 blockade with pembrolizumab). This regimen has been studied in clinical trials for metastatic PD-L1+ NSCLC and melanoma[1][2][3][4][5].
- Other names
- None
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on GRN-1201 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRN-1201 + pembrolizumab.